Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
giovedì, ottobre 22
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
LENZ Therapeutics Inc
LENZ
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$3.23
0.005
0.16%
Ult. Agg.: Oct 22, 11:27 AM
$3.25
0.03
0.93%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Dividendi
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Utili:
I risultati di Q3 2026 tra 7 giorni da adesso in gio ott 29th, prima dell'apertura del mercato
LENZ Therapeutics Financials
LENZ Therapeutics (LENZ) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
LENZ Therapeutics Q2 EPS $(1.02) Beats $(1.06) Estimate, Sales $5.486M Beat $2.373M Estimate
LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(1.02) per share which beat the analyst consensus estimate of $(1.06) by 3.77 percent. This is a 92.45 percent decrease over losses of $(0.53) per share from
Benzinga Newsdesk
PRO
LENZ Therapeutics Q1 EPS $(1.32) Misses $(1.05) Estimate, Sales $1.901M Beat $1.759M Estimate
LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimate of $(1.05) by 25.71 percent. This is a 149.06 percent decrease over losses of $(0.53) per share
Benzinga Newsdesk
Earnings Scheduled For May 11, 2026
Benzinga Insights
PRO
LENZ Therapeutics Q4 EPS $(1.16) Misses $(0.96) Estimate, Sales $1.588M Miss $1.886M Estimate
LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(1.16) per share which missed the analyst consensus estimate of $(0.96) by 20.83 percent. This is a 152.17 percent decrease over losses of $(0.46) per share
Benzinga Newsdesk
Earnings Scheduled For March 24, 2026
Benzinga Insights
PRO
LENZ Therapeutics Q3 EPS $(0.59) Beats $(0.67) Estimate, Sales $12.500M Beat $6.828M Estimate
LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $(0.67) by 11.54 percent. This is a 55.26 percent decrease over losses of $(0.38) per share from
Benzinga Newsdesk
